Betulinic Acid and Cisplatin Inhibit Metastasis Related Genes in Neuroblastoma Cells Due to Their N-MYC Status


Bayrak S., Altun Z. S., İnce D., Aktaş S., Olgun N.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.29, no.2, pp.70-78, 2019 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.4999/uhod.193154
  • Journal Name: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.70-78
  • Keywords: Betulinic acid, N-MYC, Metastases genes, Neuroblastoma, Cisplatin, ACETYL L-CARNITINE, INDUCED APOPTOSIS, RETINOIC ACID, CANCER, ACTIVATION, PROLIFERATION, EXPRESSION, INVASION, BCL-2, P53
  • Dokuz Eylül University Affiliated: Yes

Abstract

Betulinic acid-(BA) has apoptotic effects on neuroblastoma. This study explored the effects of cisplatin-(CP), BA and combination of BA and CP (BA-CP) on cell proliferation, apoptotic cell death and expressions of metastasis related genes in neuroblastoma. In this study, N-MYC positive and negative neuroblastoma cell lines, KELLY and SHSY5Y, were treated with BA, CP and BA-CP combinations. BA-CP combinations showed synergistic activity on cell growth inhibition and apoptotic cell death in both neuroblastoma cell lines. In SHSY5Y cells BA, CP or BA-CP treatments induced downregulation most of the metastatic genes' expressions. In KELLY cells, while CP treatment decreased some metastatic gene expressions, BA or BA-CP treatment reduced only DENR and RB1. BA and BA-CP showed prominent effect on metastasis related gene expressions in predominantly KELLY cells. The results of this study suggest that BA may be a promising anti-cancer agent for neuroblastoma treatment, whereas CP is still the most suitable chemotherapeutic drug for aggressive neuroblastoma.